Nabriva Therapeutics plc Total Assets 2011-2026 | NBRV

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Nabriva Therapeutics plc

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
31.8 M	80.9 M	58.4 M	94.1 M	110 M	95.8 M	93.2 M	118 M	4.82 M	7.35 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
118 M	4.82 M	69.5 M

Quarterly Total Assets Nabriva Therapeutics plc

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
24.3 M	31.8 M	48.2 M	-	65.8 M	80.9 M	89.1 M	95.4 M	79.4 M	58.4 M	58.4 M	58.4 M	58.4 M	94.1 M	94.1 M	94.1 M	94.1 M	110 M	110 M	110 M	110 M	95.8 M	95.8 M	95.8 M	95.8 M	93.2 M	93.2 M	93.2 M	93.2 M	118 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
118 M	24.3 M	84.2 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	11.2 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	92.2 M	-	-	$ 269 M	USA
Enlivex Therapeutics Ltd. ENLV	2.33 B	$ 0.77	-4.12 %	$ 35.2 M	Israel
Exelixis EXEL	2.84 B	$ 48.16	4.22 %	$ 13.1 B	USA
BioNTech SE BNTX	22 B	$ 94.13	1.19 %	$ 22.8 B	Germany
Fortress Biotech FBIO	186 M	$ 2.39	-0.42 %	$ 66.7 M	USA
Forte Biosciences FBRX	82.8 M	$ 24.02	-8.22 %	$ 311 M	USA
Compugen Ltd. CGEN	157 M	$ 2.9	1.4 %	$ 271 M	Israel
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
ACADIA Pharmaceuticals ACAD	1.19 B	$ 22.4	-0.71 %	$ 3.71 B	USA
Genmab A/S GMAB	45.8 B	$ 26.43	-2.33 %	$ 1.71 B	Danmark
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	466 M	$ 3.14	-	$ 653 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.51	-0.85 %	$ 5.78 M	Israel
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
Gilead Sciences GILD	59 B	$ 131.33	-2.04 %	$ 163 B	USA
Genprex GNPX	10.2 M	$ 0.87	0.58 %	$ 811 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 21.17	2.47 %	$ 2.69 B	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Grifols, S.A. GRFS	21.4 B	$ 8.1	0.5 %	$ 5.51 B	Spain
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
CRISPR Therapeutics AG CRSP	2.27 B	$ 54.83	4.6 %	$ 4.93 B	Schweiz
Avenue Therapeutics ATXI	2.93 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	589 M	$ 1.57	-2.48 %	$ 418 M	Britain